The European Commission has rubberstamped a recommendation for approval for the Kixelle (insulin aspart) biosimilar to Novo Nordisk’s NovoRapid, handing a significant marketing authorization to the newly-formed Viatris and its development partner Biocon.
“While management has not indicated specific launch timing of the approved Kixelle, we believe it will be commercialized during the...






